BRIEF-Cytrx up 8.5 percent premarket

NEW YORK Tue Jan 21, 2014 7:55am EST

NEW YORK Jan 21 (Reuters) - CytRx Corp : * Up 8.5 percent to $7.64 premarket; gets FDA OK to extend aldoxorubicin dosing cycles in late-stage trial for soft tissue sarcomas

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.